Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ4768MR)

This product GTTS-WQ4768MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001145645.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	10673
UniProt ID	Q9Y275

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4768MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ11674MR	IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	MHAA4549A
GTTS-WQ7194MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	FMC63 scFv-8A-F9Z CAR
GTTS-WQ11500MR	IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MetMAb
GTTS-WQ14867MR	IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	SGN-LIV1A
GTTS-WQ7602MR	IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	G-CSF-Fc-PEG
GTTS-WQ10247MR	IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	LFB-R603
GTTS-WQ12386MR	IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	NEOD-001
GTTS-WQ7818MR	IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	GSK 716155

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST